Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review

Kendzierski, Daniel C.; Schneider, Bryan P.; Kiel, Patrick J.

doi:10.1016/j.clbc.2018.04.005

Cited by 15 publications

(10 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of several studies indicate that long-acting LHRHas effectively suppress ovarian function, based on measurements of the E2 levels, similar to short-acting agents ( 16 – 19 ). Our study of 6M LHRHa+tamoxifen-treated patients showed that the E2 levels measured after drug administration were mostly in the menopausal range.…”

Section: Discussionmentioning

confidence: 99%

“…Kendzierski et al. ( 19 ) reported studied OFS therapy plus an aromatase inhibitor, and their retrospective review comparing 1-month (n = 100) versus 3-month dosages of (n = 101) an LHRHa + aromatase inhibitor showed no difference in the E2 levels after 3 months of administration ( 19 ). Most patients visit our clinic every 6 months according to the guidelines for breast cancer treatment; thus, prior consideration was given to 6 months of LHRHa administration in patients undergoing OFS therapy.…”

Section: Discussionmentioning

confidence: 99%

“…However, to reduce the associated side effects, discomfort, and inconvenience, drug dosage regimens at 3-month or 6month (6M) intervals have been developed for treatment, and several clinical studies have demonstrated no difference in their safety and effectiveness compared with 1-month regimens (11,(16)(17)(18)(19). The anticancer activity of LHRHas is inherently aimed at effectively suppressing E2 levels to postmenopausal levels.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer

Lee

Kim

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundIn patients with hormone receptor-positive (HR+)/premenopausal breast cancer, luteinizing hormone-releasing hormone analogs (LHRHas) are used as standard endocrine treatment. Based on previous clinical studies, 1-month formulations are recommended in most breast cancer treatment guidelines, but long-acting formulations facilitate reductions in side effects and patient discomfort caused by frequent administration. However, few efficacy studies have been conducted on 6-month formulations. Therefore, this study aimed to evaluate the efficacy of 6-month formulations of LHRHas.MethodsThis retrospective study was conducted from January 2018 to December 2019 and involved premenopausal patients with HR+ breast cancer administered 6-month LHRHas as adjuvant treatment after surgery, and those previously administered chemotherapy or other LHRHa types were excluded. Patients’ estradiol (E2) and follicle-stimulating hormone (FSH) levels were measured before surgery, and their E2 levels were also measured at 3, 6, 12, 18, and 24 months at periodic postsurgical examinations.ResultsA total of 228 patients were included, and the median patient age was 44 (range, 25–54) years. The mean serum E2 and FSH levels before surgery were 69.7 (range, 4–683) pg/mL and 7.3 (range, 0.4–88.9) mIU/mL, respectively, whereas the mean serum E2 level monitored at intervals during the 6-month LHRHa administration was 5.5 (range, 4.0–52) pg/mL. No women menstruated during the follow-up period after the LHRHas administration, and the E2 levels were less than 30 pg/mL in all patients except one.ConclusionsThe 6-month LHRHa formulation adequately suppressed ovarian function in premenopausal patients with HR+ breast cancer. This indicates that long-acting LHRHas can be effectively used for patient convenience and that there is high compliance with long-term use.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer

Lee

Kim

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…These studies demonstrated comparable DFS and OS rates compared to the monthly formulation. 16,[65][66][67] Interventions to further reduce time in clinic should also include elimination or abbreviating infusion observation periods for select regimens that have a risk of delayed infusion reactions. Trastuzumab labeling states patients must be monitored for 6 hours after the start of infusion.…”

Section: Extending Therapeutic Intervals and Minimizing Chair Timementioning

confidence: 99%

“…These studies demonstrated comparable DFS and OS rates compared to the monthly formulation. 16,65–67…”

Section: Altering System Cancer Regimensmentioning

confidence: 99%

Clinical strategies for optimizing infusion center care through a pandemic

Hanna

Segal

Barlow

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

The national pandemic resulting from the novel coronavirus, COVID-19, has made the delivery of care for patients with cancer a challenge. There are competing risks of mortality from cancer versus serious complications and higher risk of death from COVID-19 in immunocompromised hosts. Furthermore, compounding these concerns is the inadequate supply of personal protective equipment, decreased hospital capacity, and paucity of effective treatments or vaccines to date for COVID-19. Guidance measures and recommendations have been published by national organizations aiming to facilitate the delivery of care in a safe and effective manner, many of which, are permanently adoptable interventions. Given the critical importance to continue chemotherapy, there remains additional interventions to further enhance patient safety while conserving healthcare resources such as adjustments in medication administration, reduction in laboratory or drug monitoring, and home delivery of specialty infusions. In this manuscript, we outline how to implement these actionable interventions of chemotherapy and supportive care delivery to further enhance the current precautionary measures while maintaining safe and effective patient care. Coupled with current published standards, these strategies can help alleviate the numerous challenges associated with this pandemic.

show abstract

Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer

Sukumar

Quiroga

Kassem

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review

Abstract: Leuprolide acetate depot administered every 3 months is as efficacious and tolerable as a monthly injection in combination with an aromatase inhibitor for premenopausal patients with hormone receptor-positive breast cancer.

Cited by 15 publications

References 4 publications

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer

Clinical strategies for optimizing infusion center care through a pandemic

Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer

Contact Info

Product

Resources

About